Starling Oncology (STLNW) Accumulated Expenses (2019 - 2026)

Starling Oncology (STLNW) has reported Accumulated Expenses for 8 consecutive years, with $27.4 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Accumulated Expenses rose 19.85% year-over-year to $27.4 million; the trailing twelve-month figure through Jun 2026 stood at $27.4 million (up 19.85% YoY), and the FY2025 full-year result was $20.6 million, down 2.15% from the prior year.
• Accumulated Expenses advanced to $27.4 million in Q2 2026 per STLNW's latest filing, from $24.3 million in the prior quarter.
• Across five years, Accumulated Expenses topped out at $27.4 million in Q2 2026 and bottomed at $12.2 million in Q1 2023.
• Historically, Accumulated Expenses has averaged $18.1 million across 5 years, with a median of $16.9 million in 2022.
• The sharpest annual moves came in 2022 and 2023: Accumulated Expenses soared 18045.0% in 2022, then retreated 21.21% in 2023.
• Over 5 years, Accumulated Expenses stood at $14.6 million in 2022, then fell by 4.1% to $14.0 million in 2023, then jumped by 50.71% to $21.1 million in 2024, then slipped by 2.15% to $20.6 million in 2025, then surged by 32.93% to $27.4 million in 2026.
• According to Business Quant data, Accumulated Expenses over the past three periods registered $27.4 million, $24.3 million, and $20.6 million for Q2 2026, Q1 2026, and Q4 2025 respectively.